Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

AC Immune Targeting $50m IPO

Executive Summary

Alzheimer's disease drug and vaccine developer AC Immune SA is aiming to raise $50m via an initial public offering that will take the company public on Nasdaq in the US. This follows a successful series E financing round in May this year that saw the company net $43.5m.

Advertisement

Related Content

IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
IPO Update: Haircuts Needed To Price Biotech Offerings

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065317

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel